Topical Ophthalmic Liposomes Dual-Modified with Penetratin and Hyaluronic Acid for the Noninvasive Treatment of Neovascular Age-Related Macular Degeneration
Chen Sun,Shuyue Zhang,Nan Xu,Kun Liu,Fang Wei,Xiaoqian Zhang,Jigang Zhang,Shen Gao,Yuan Yu,Xueying Ding
DOI: https://doi.org/10.2147/ijn.s446425
IF: 7.033
2024-02-23
International Journal of Nanomedicine
Abstract:Chen Sun, 1, &ast Shuyue Zhang, 1, &ast Nan Xu, 1, &ast Kun Liu, 2 Fang Wei, 2 Xiaoqian Zhang, 1 Jigang Zhang, 1 Shen Gao, 3 Yuan Yu, 4 Xueying Ding 1 1 Clinical Research Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, People's Republic of China; 2 Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai General Hospital, Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai, 200040, People's Republic of China; 3 Department of Pharmacy, Changhai Hospital, Second Military Medical University, Shanghai, 200433, People's Republic of China; 4 Department of Pharmacy, Naval Medical University, Shanghai, 200433, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xueying Ding, Clinical Research Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, People's Republic of China, Email Yuan Yu, Department of Pharmacy, Naval Medical University, Shanghai, 200433, People's Republic of China, Email Introduction: Since intrinsic ocular barrier limits the intraocular penetration of therapeutic protein through eye drops, repeated intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents are the standard therapy for neovascular age-related macular degeneration (nAMD), which are highly invasive and may cause particular ocular complications, leading to poor patient compliance. Methods: Using Penetratin (Pen) as the ocular penetration enhancer and hyaluronic acid (HA) as the retina-targeting ligand, a dual-modified ophthalmic liposome (Penetratin hyaluronic acid-liposome/Conbercept, PenHA-Lip/Conb) eye drop was designed to non-invasively penetrate the ocular barrier and deliver anti-VEGF therapeutic agents to the targeted intraocular tissue. Results: PenHA-Lip effectively penetrates the ocular barrier and targets the retinal pigment epithelium via corneal and non-corneal pathways. After a single topical administration of conbercept-loaded PenHA-Lip (PenHA-Lip/Conb), the intraocular concentration of conbercept peaked at 18.74 ± 1.09 ng/mL at 4 h, which is 11.55-fold higher than unmodified conbercept. In a laser-induced choroidal neovascularization (CNV) mouse model, PenHA-Lip/Conb eye drops three times daily for seven days inhibited CNV formation and progression without any significant tissue toxicity and achieved an equivalent effect to a single intravitreal conbercept injection. Conclusion: PenHA-Lip efficiently and safely delivered conbercept to the posterior eye segment and may be a promising noninvasive therapeutic option for nAMD. Keywords: ocular drug delivery, dual-modified liposomes, Penetratin, hyaluronic acid, conbercept Graphical Globally, age-related macular degeneration (AMD) is a chronic ocular disease that is the leading cause of irreversible vision loss in elderly patients. 1–3 In neovascular age-related macular degeneration (nAMD), choroidal neovascularization breaks through Bruch's membrane and grows into the retina through vascular endothelial growth factor (VEGF) stimulation. 4 The intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents effectively alleviates disease progression by competitively inhibiting the binding of VEGF to its cognate receptors (VEGFR). Currently, anti-VEGF therapy, mostly administered through intravitreal injection, is the standard treatment for wet AMD. 5 Conbercept (Conb) is the first self-developed anti-VEGF drug approved in China and is a 143 kDa recombinant gene fusion protein composed of VEGF-binding domains and the Fc portion of human immunoglobulin G-1. Compared with other anti-VEGF drugs, conbercept has high VEGF-binding specificity and affinity 6 , relatively higher molecular weight (143kD), 7–9 and is well tolerated by patients, 10 with its affinity for VEGF is 50-fold and 30-fold higher than that of bevacizumab and ranibizumab, respectively. 11,12 Therefore, intravitreal therapy is widely used in the Chinese clinical practice. However, this invasive procedure can lead to ocular complications including cataracts, vitreous hemorrhage, retinal detachment, and intraocular inflammation. 13,14 Repeated injections or even lifelong treatment may further increase psychological and economic burden, resulting in poor patient compliance. 2 Therefore, less-invasive alternatives -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology